Format

Send to

Choose Destination
J Med Virol. 2018 Feb;90(2):304-312. doi: 10.1002/jmv.24903. Epub 2017 Nov 9.

Real-world effectiveness of sofosbuvir-based treatment regimens for chronic hepatitis C genotype 3 infection: Results from the multicenter German hepatitis C cohort (GECCO-03).

Author information

1
I. Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
2
Center for Infectiology Berlin (CIB), Berlin, Germany.
3
CIM Infectious Diseases, Muenster, Germany.
4
Practice for Gastroenterology Herne, Herne, Germany.
5
Infektiologikum, Frankfurt, Germany.
6
Practice for Gastroenterology Leverkusen, Leverkusen, Germany.
7
Infektionsmedizinisches Centrum Hamburg (ICH), Hamburg, Germany.
8
I. Department of Medicine, University Hospital Bonn, Bonn, Germany.
9
Center for HIV and Hepatogastroenterology, Duesseldorf, Germany.
10
Division of Computational and Systems Medicine, Department of Surgery and Cancer, FoM, Imperial College London, London, United Kingdom.
11
German, Center for Infection Research (DZIF), Hamburg-Site, Germany.

Abstract

There are limited data regarding the real world effectiveness of direct acting antivirals (DAA) for the therapy of chronic genotype 3 hepatitis C virus (HCV) infection. All HCV genotype 3 infected patients from the German hepatitis C cohort (GECCO), which is a prospective database of nine German hepatitis C treatment centers, were included in the study. Three hundred forty-two chronically infected HCV genotype 3 patients were analyzed (253 males [74.0%], mean age 47.3 years, 127 cirrhotic patients [37.1%] mostly with Child A cirrhosis, 113 treatment experienced patients [37.1%], 38 HCV/HIV co-infected patients [11.1%]). SVR12 rates in the "intention-to-treat" analysis were as follows: sofosbuvir/ribavirin 69.4% (75/108), sofosbuvir/peginterferon/ribavirin 80.6% (58/72), sofosbuvir/daclatasvir ± ribavirin for 12 weeks 88.3% (53/63), sofosbuvir/daclatasvir ± ribavirin for 24 weeks 79.3% (23/29), sofosbuvir/ledipasvir ± ribavirin for 12 weeks 71.4% (10/14), and sofosbuvir/ledipasvir ± ribavirin for 24 weeks 86.7% (26/30). Forty patients were lost to follow-up, 23 patients had a relapse, 4 patients stopped treatment prematurely and 1 patient died. Female sex (P = 0.038) and treatment with two different DAAs (P = 0.05) were predictors for SVR12 in the multivariate analysis. In conclusion, sofosbuvir/daclatasvir ± ribavirin for 12 weeks and sofosbuvir/ledipasvir ± ribavirin for 24 weeks are effective for the treatment of HCV genotype 3 infected patients including cirrhotic, treatment-experienced or HIV/HCV co-infected patients.

KEYWORDS:

HCV; HIV; daclatasvir; direct acting antivirals; ledipasvir

PMID:
28710853
DOI:
10.1002/jmv.24903
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center